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Abstract
Background: Data from population-based cancer registries are increasingly used to conduct research and guide
policy. However, few validation studies of cancer registry data have been conducted, particularly among children.
We therefore aimed to determine the validity of pediatric diagnostic data in the Ontario Cancer Registry (OCR).
Methods: All children diagnosed with any malignancy between 2000–2011 in Ontario, Canada were identified through
the Pediatric Oncology Group of Ontario Networked Information System (POGONIS), a pediatric cancer registry actively
maintained by trained data managers, and linked to the OCR. International Classification of Diseases for Oncology codes
for each patient were taken from the OCR and converted to International Classification of Childhood Cancer (ICCC-3)
diagnostic groups and subgroups using published algorithms. OCR-based ICCC-3 groupings were then validated by
comparing them to gold standard diagnostic information from POGONIS.
Results: A total of 4448 patients met inclusion criteria; 4073 (91.6 %) were successfully linked to the OCR. Diagnostic
accuracy was excellent for many childhood solid tumors. For example, the OCR correctly identified all cases of
retinoblastoma [kappa = 1.00, 95th confidence interval (CI) 1.00–1.00] and nearly all cases of neuroblastoma (kappa = 0.97,
95th CI 0.96–0.99). Hematologic and central nervous system (CNS) cancers, the most common childhood malignancies,
were however often misclassified with inferior kappas (acute lymphoblastic leukemia – 0.77, 95th CI 0.75–0.80; Burkitt
lymphoma – 0.02, 95th CI 0.02–0.07).
Conclusions: Misclassification of common pediatric hematologic and CNS cancers was significant and may lead to
inaccurate incidence and survival estimates using cancer registry data. Validation studies of pediatric data in other
registries are necessary to identify practices and procedures leading to the highest quality information.
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Background
Population-based cancer registries have proven an invalu-
able resource for both cancer researchers and policy-
makers [1]. Cancer registry data have been used to derive
population-based estimates of outcome and to track
changes in incidence in both adults and children [2–4]. In
addition, when linked to other health administrative data,
they have also provided a rich source with which to
conduct comparative effectiveness research and guide
government policy [1, 3].
Cancer registries are often considered gold standards
against which other data sources are validated [5, 6]. Des-
pite their impact upon both care and policy, very few stud-
ies have examined the validity of cancer registries
themselves. Most determinations of validity have relied on
indirect measures such as the percentage of cases that are
microscopically verified or the proportion of cases identi-
fied only by death certificates [7]. Studies involving re-
abstractions or comparisons to the source medical records
are less common [8, 9]. While several studies have reported
favorably when estimating the completeness of capture of
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childhood cancer cases in cancer registries, the ability of
general cancer registries to accurately describe incident
cancer cases may differ between adult and pediatric malig-
nancies [10, 11]. Unlike adult malignancies, pediatric diag-
noses are more heavily dependent on histology and not site;
they also represent a heterogeneous group of malignancies
that make up only 1 % of the total cancer burden [12]. Al-
gorithms and personnel employed by registries may there-
fore be heavily influenced by adult oncology, and
consequently fail to validly capture childhood cases. This
may be of particular concern in malignancies that are
unique to childhood.
Our objective was therefore to validate the diagnosis
data contained in a provincial cancer registry covering all
ages for a population-based cohort of pediatric oncology
patients. We were able to achieve this objective by taking
advantage of the unique data sources available in Ontario
Canada, which include two population-based cancer regis-
tries: one general passive registry and one active pediatric-
specific registry. While the completeness of these two
registries has previously been compared, no study has
compared specific data elements common to both [11].
Diagnosis data in the general cancer registry were there-
fore compared to that in the pediatric registry.
Methods
Data sources
The Pediatric Oncology Group of Ontario Networked In-
formation System (POGONIS) is a population-based regis-
try capturing data on all cases of Ontario pediatric cancer
diagnosed at pediatric oncology centers. Pediatric oncology
care in Ontario is delivered through five tertiary centers
and their associated satellite centers. POGONIS collects
data through an active process; trained data managers at
each of the five tertiary centers prospectively and actively
abstract demographic, disease, treatment and outcome data
for all new cancer cases. Data managers routinely attend
tumor boards and other medical rounds to ensure com-
pleteness and validity of the data, including diagnosis. Se-
nior POGONIS administrators also review these data
centrally to assess accuracy; data managers are routinely
contacted for clarification of certain data elements, and can
be asked to return to the patient chart if necessary. Data
managers in turn contact treating clinicians if necessary.
Previous work has shown that POGONIS identifies greater
than 96 % of Ontario children with cancer aged 0–14 years
[11]. Adolescents treated at adult institutions are not identi-
fiable through POGONIS, leading to lower capture rates
within POGONIS of patients aged 15–18 years.
Covering a population of approximately 13 million, the
Ontario Cancer Registry (OCR) is a population-based
tumor registry which relies on the passive receipt of reports
from four sources: pathology reports with a diagnosis of
cancer from all pathology labs across the province, hospital
discharge records containing a diagnosis of cancer from all
hospitals across Ontario, electronic health records from
specific treatment centers, and any electronic death record
with cancer as one of the underlying causes [13, 14]. During
the study period, computerized algorithms employing
deterministic and probabilistic linkage were used to link
multiple records pertaining to the same individual. In
contrast to POGONIS, during the study period OCR
employed a set of computerized rules to passively assign
the site and histology of the primary malignancy. Given this
passive process, OCR was not able to return to source doc-
uments for additional data or clarifications, nor was OCR
able to incorporate from additional data sources such as
POGONIS.
Study population
All Ontario residents diagnosed with any malignancy be-
tween 2000 and 2011, less than 18 years of age at diagnosis,
and treated and registered at a pediatric oncology center
were identified using POGONIS and included. Patients
with histiocytic disorders such as Langerhans cell histiocy-
tosis or hemophagocytic lymphohistiocytosis were excluded
given their variable inclusion in OCR over the study period.
The study eligibility end date of 2011 was chosen to
maximize the eligible cases be registered in both databases.
Determining OCR diagnoses
As noted above, and in contrast to adult classification sys-
tems, pediatric cancers are generally categorized according
to morphology and not primary site of origin. The third
edition of the International Classification of Childhood
Cancer (ICCC-3) is currently accepted as the standard clas-
sification system for childhood cancer [15]. The ICCC-3
operates hierarchically, with 12 main Level 1 diagnostic
groups and 47 Level 2 diagnostic subgroups. For certain
heterogeneous subgroups, Level 3 optional extended classi-
fications are provided. As an example, Diagnostic Group I
corresponds to leukemias, myeloproliferative diseases, and
myeloplastic diseases, with Diagnostic Subgroup Ia pertain-
ing to lymphoid leukemias and extended classification Ia.1
designating precursor cell leukemias. The ICCC-3 also in-
cludes an algorithm which converts International Classifica-
tion of Diseases for Oncology, third edition (ICD-O-3),
codes (ICD-O-M, ICD-O-T) to ICCC-3 diagnostic groups
and subgroups [15]. ICCC-3 diagnostic groups are mainly
based on morphology codes indicated by morphology
(ICD-O-M), but are sometimes also dependent on topog-
raphy codes (ICD-O-T) [16]. For example, cases with
morphology codes indicating histologies consistent with
germ cell tumors (e.g. 9071 – yolk sac tumor, 9080 – tera-
toma) are further classified by ICCC-3 as gonadal, intracra-
nial/intraspinal, or extracranial/extragonadal based upon
ICD-O-T codes.
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Similar to most population-based cancer registries, the
OCR uses ICD-O-3 codes to classify incident cases. Using
the aforementioned algorithm, we converted these ICD-
O-3 codes to ICCC-3 diagnostic groups and subgroups
(see Fig. 1 for schematic overview). As ICD-O-T codes
were unavailable for the study population, we first con-
verted OCR ICD-9 codes that indicated site of disease to
ICD-O-T codes (Fig. 1). For example, we converted the
ICD-9 code 189.0 (malignant neoplasm of kidney, except
pelvis) and its derivatives to the ICD-O-T code C64.9,
which indicates a primary renal site of disease. Additional
examples may be seen in Additional file 1.
Importantly, as ICD-O-M codes were available from
OCR, the information from these ICD-O-M codes were
the only data source used to determine histology/
morphology, even if additional or contrary information
was available from the OCR ICD-9 codes. This decision
was made as the published conversion algorithm to
ICCC-3 uses only ICD-O-M codes for histology/morph-
ology data and not ICD-9 codes [15]. Our approach
should thus mimic that endorsed by the literature for
use by researchers and cancer registrars.
Several additional modifications were necessary:
1. A small number of morphology codes from either
previous ICD-O editions or more recently introduced
were encountered in the OCR. These codes were first
mapped to ICD-O-3 morphology/histology codes be-
fore the conversion to ICCC-3 (Additional file 2).
2. Patients for whom no ICD-O-M code was listed or for
whom codes indicating solely “malignant primary” were
classified as Diagnostic Subgroup XIIb, or “Other un-
specified malignant tumors”. Patients coded as 9990/3,
or “No mircoscopic proof”, were similarly classified. As
noted above, ICD-9 codes were not used in these cases
in order to clarify histology/morphology.
3. Rhabdoid tumors are rare malignancies that share a
characteristic histology and which occur primarily in
the brain (known as atypical teratoid/rhabdoid tumors
– AT/RT) and kidney [17]. The ICCC-3 algorithm clas-
sifies any tumor with ICD-O-M code 9508/3 (AT/RT)
as an AT/RT (IIIc.4) regardless of site, and tumors with
ICD-O-M code 8963/3 (malignant rhabdoid tumor) as
either rhabdoid renal tumors (VIa.2) or extrarenal rhab-
doid tumors (IXd.3) depending on site. The algorithm
however does not account for patients with ICD-O-M
code 8963/3 with a central nervous system primary site.
We classified these patients as having AT/RT (IIIc.4).
Determining POGONIS diagnoses
POGONIS was established in 1985, prior to the existence
of internationally recognized classification systems for
childhood cancer. Malignancies are therefore categorized in
POGONIS using a unique classification system derived by
local clinicians that nonetheless shares similarities with the
ICCC-3. Each POGONIS diagnosis code was mapped to
the appropriate ICCC-3 category; an example is illustrated
in Additional file 3. Rare pediatric malignancies such as
squamous cell carcinomas and malignant carcinoid tumors
were coded in POGONIS as single diagnostic categories
independent of site, unlike in the ICCC-3. For these tu-
mors, site of disease information was also extracted from
Fig. 1 Schematic overview of study methodology and data sources
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POGONIS to allow accurate ICCC-3 categorization. Rare
cases for which only general diagnoses were available (e.g.
“bone tumor”) were mapped to ICCC-3 Level 1 diagnostic
groups only. Other demographic variables were also ob-
tained from POGONIS, including age at diagnosis, gender,
and time period (early, 2000–2005 vs. late, 2006–2011).
Validation of OCR diagnoses
Cohort patients were linked to the OCR deterministically
by individually assigned Ontario Health Insurance Pro-
gram numbers. Where deterministic linkage was not pos-
sible due to a lack of an exact health insurance number
match, probabilistic linkage using name, date of birth and
gender was employed. All patients linked probabilistically
were reviewed for linkage quality. For those patients suc-
cessfully linked, OCR-based and POGONIS-based ICCC-
3 classifications were compared. Comparisons were made
by Level 1 diagnostic groups and where appropriate, Level
2 and Level 3 subgroups. Given its use of pediatric-trained
data managers, active capture of data, clinician involve-
ment, and ability to correct and supplement data when
needed, the POGONIS-based classification was consid-
ered the gold standard against which the OCR-based clas-
sification was validated.
Analyses
Successfully and unsuccessfully linked patients were com-
pared by age, gender, and time period of diagnosis using
the Chi square test or the Wilcoxon rank sum test as ap-
propriate. Guidelines pertaining to studies validating health
administrative data have recommended the use of multiple
statistical measures of agreement [18]. Agreement between
the POGONIS-based and OCR-based classifications was
therefore assessed by calculating the kappa statistic, sensi-
tivity, specificity, positive predictive value and negative pre-
dictive value. Statistical significance was defined as p < 0.05.
Results
Using POGONIS, 4448 patients were identified as meeting
study cohort inclusion criteria (Fig. 2). Of these, 4073
(91.6 %) were successfully linked to the OCR. Linked and
unlinked patients showed no differences in age [median
6 years, (interquartile range - IQR 3–13) vs. 8 years (2–
13); p = 0.53] or gender [2223/4073 (54.6 %) male vs. 196/
374 (52.4 %); p = 0.42]. Unlinked patients were more likely
to have been diagnosed in the late time period [170/375
(45.3 %) vs. 1598/4073 (35.9 %); p = 0.02]. Of the 375 un-
linked patients, 54 were subsequently added to the OCR
after the data cut, accounting for the time period findings.
The remaining 321 unlinked cases were deemed to have
linkages of insufficient quality. Of the 4073 successfully
linked patients, 3693 (90.7 %) were linked deterministic-
ally by health card number. A total of 380 (9.3 %) were
linked probabilistically, with 357 (93.9 %) linked based on
exact date of birth and a phonetic encoding of surname
and the remaining based on various combinations of the
linkage variables.
Mapping POGONIS diagnostic codes to ICCC-3 re-
sulted in the successful assignment of ICCC-3 Level 1
diagnostic groups to all patients and of Level 2 diagnostic
subgroups to all but 25 (0.6 %) patients. These latter 25
were retained in the linkage exercise. Mapping OCR codes
resulted in the successful assignment of ICCC-3 diagnos-
tic groups and subgroups to all patients. Table 1 illustrates
the number of children classified by POGONIS and by the
OCR into each ICCC-3 Level 1 diagnostic group, as well
as the sensitivity, specificity, and positive and negative pre-
dictive values of the OCR-based diagnostic categories as
compared to the gold standard POGONIS-based categor-
ies. The kappa statistics of agreement are also listed. With
the exception of Diagnostic Group XII (Other and un-
specified malignant neoplasms), kappas were generally ex-
cellent (>0.80), [19] ranging from 0.86 to 1.00. Again
excepting Diagnostic Group XII, sensitivities ranged from
0.82 to 1.00. While POGONIS classified only 23 (0.5 %)
patients in diagnostic group XII, using OCR data resulted
in 259 (6.3 %) patients classified thusly.
Table 2 illustrates the same parameters for selected
ICCC-3 diagnostic subgroups (Level 2 and 3). Measures
of agreement remained excellent for some subgroups,
Fig. 2 Patient linkage
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including Hodgkin lymphoma, neuroblastoma, nephroblas-
toma, hepatoblastoma and osteosarcoma. However, agree-
ment for several diagnostic subgroups was significantly
inferior, with kappa statistics of 0.77 for acute lymphoblastic
leukemia (ALL), 0.71 for non-rhabdomyosarcoma soft tis-
sue sarcomas, 0.24 for lymphoblastic lymphomas, and 0.02
for Burkitt lymphomas.
We then more closely examined reasons for discrep-
ancy among the above three diagnostic subgroups (ALL,
lymphoblastic lymphoma, Burkitt lymphoma), represent-
ing common childhood cancers but with poor measures
of agreement. Of 1070 patients classified by POGONIS
as having ALL, 311 (29.1 %) were improperly classified
by the OCR. The most common OCR ICD-O-M codes
found among these children were 9990/3 (N = 119,
38.2 % - clinically malignant tumor), 9831/3 (N = 118,
37.9 % - chronic lymphoproliferative disorder of NK-
cells) and 9801/3 (N = 23, 7.4 % - acute leukemia, NOS).
Table 1 Measures of agreement between OCR-based and POGONIS-based diagnostic groups
Malignancy type N, POGONIS N, OCR Kappa (95 % CI) Sensitivity Specificity PPV NPV
I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases 1305 1143 0.89 (0.88–0.91) 0.87 1.00 0.99 0.94
II. Lymphomas and reticuloendothelial neoplasms 585 554 0.90 (0.88–0.92) 0.89 0.99 0.94 0.98
III. CNS and miscellaneous intracranial and intraspinal neoplasms 790 757 0.95 (0.94–0.96) 0.94 1.00 0.98 0.99
IV. Neuroblastoma and other peripheral nervous cell tumors 262 256 0.97 (0.96–0.99) 0.96 1.00 0.98 1.00
V. Retinoblastoma 105 105 1.00 (1.00–1.00) 1.00 1.00 1.00 1.00
VI. Renal tumors 174 175 0.98 (0.96–0.99) 0.98 1.00 0.98 1.00
VII. Hepatic tumors 68 64 0.92 (0.88–0.97) 0.90 1.00 0.95 1.00
VIII. Malignant bone tumors 181 192 0.89 (0.86–0.92) 0.92 0.99 0.87 1.00
IX. Soft tissue and other extraosseus sarcomas 285 260 0.86 (0.82–0.89) 0.82 0.99 0.91 0.99
X. Germ cell tumors, trophoblastic tumors, and neoplasms of gonads 140 136 0.96 (0.93–0.98) 0.94 1.00 0.97 1.00
XI. Other malignant epithelial neoplasms and malignant melanomas 155 172 0.93 (0.90–0.96) 0.98 0.99 0.88 1.00
XII. Other and unspecified malignant neoplasms 23 259 0.06 (0.02–0.10) 0.43 0.94 0.04 1.00
CI confidence interval, CNS central nervous system, N number, NPV negative predictive value, OCR Ontario Cancer Registry, POGONIS Pediatric Oncology Group of
Ontario Networked Information System, PPV positive predictive value
Table 2 Measures of agreement between selected OCR-based and POGONIS-based diagnostic subgroups
Malignancy type N, POGONIS N, OCR Kappa (95 % CI) Sensitivity Specificity PPV NPV
Ia.1. Precursor cell leukemias (acute lymphoblastic leukemia) 1070 775 0.77 (0.75–0.80) 0.71 0.99 0.98 0.91
Ib. Acute myeloid leukemias 187 164 0.84 (0.81–0.89) 0.80 1.00 0.91 0.99
IIa. Hodgkin lymphomas 312 310 0.99 (0.98–1.00) 0.98 1.00 0.99 1.00
IIb-IId, IIe. Non Hodgkin lymphomas 271 244 0.78 (0.74–0.82) 0.76 0.99 0.84 0.98
IIb.1 Precursor cell lymphomas (lymphoblastic lymphomas) 67 22 0.24 (0.12–0.36) 0.16 1.00 0.50 0.99
IIc. Burkitt lymphomas 78 1 0.02 (0.02–0.07) 0.01 1.00 1.00 0.98
IIIb. Astrocytomas 446 343 0.82 (0.79–0.85) 0.74 1.00 0.96 0.97
IIIa1. Ependymomas 72 69 0.95 (0.91–0.99) 0.93 1.00 0.97 1.00
IIIc. Intracranial and intraspinal embryonal tumors 199 201 0.91 (0.87–0.94) 0.91 1.00 0.91 1.00
IIIc.1 Medulloblastomas 152 134 0.91 (0.88–0.95) 0.86 1.00 0.98 1.00
IIIx. All other CNS tumors 73 144 0.34 (0.26–0.43) 0.53 0.97 0.27 0.99
IVa. Neuroblastoma and ganglioneurblastoma 259 254 0.97 (0.96–0.99) 0.97 1.00 0.98 1.00
VIa.1 Nephroblastoma 141 140 0.98 (0.97–1.00) 0.98 1.00 0.99 1.00
VIIa. Hepatoblastoma 58 56 0.96 (0.93–1.00) 0.95 1.00 0.98 1.00
VIIIa. Osteosarcoma 88 87 0.96 (0.93–0.99) 0.95 1.00 0.97 1.00
VIIIc. Ewing tumor and related sarcomas of bone 82 93 0.81 (0.74–0.87) 0.87 0.99 0.76 1.00
IXa. Rhabdomyosarcomas 116 128 0.92 (0.89–0.96) 0.97 1.00 0.88 1.00
IXb-IXe. Non-rhabdomyosarcoma soft tissue sarcomas 153 132 0.71 (0.65–0.77) 0.67 0.99 0.78 0.99
CI confidence interval, CNS central nervous system, N number, NPV negative predictive value, OCR Ontario Cancer Registry, POGONIS Pediatric Oncology Group of
Ontario Networked Information System, PPV positive predictive value
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Interestingly, 244/311 (78.5 %) were correctly identified
as having ALL by OCR ICD-9 codes. 16 children were
incorrectly diagnosed as having ALL by OCR; the most
common correct diagnoses in POGONIS for these chil-
dren were acute mixed-lineage leukemia (N = 6, 37.5 %)
and lymphoblastic lymphoma (N = 5, 31.3 %).
Of 67 children with lymphoblastic lymphoma according
to POGONIS data, 56 (83.6 %) were misclassified by the
OCR. The most common OCR ICD-O-M code found
among these patients was 9590/3 (37, 66.1 % - malignant
lymphoma, NOS). Using OCR ICD-9 codes would not have
correctly identified these children; 36 (64.3 %) were coded
as having “other lymphomas” while another 10 (17.9 %)
were coded as having “lymphosarcoma”. 11 children were
incorrectly identified as having lymphoblastic lymphoma by
OCR; according to POGONIS, 8 (72.7 %) of these children
in fact had ALL.
Of the 78 children categorized as having Burkitt lymph-
oma by POGONIS, nearly all were misclassified by the
OCR (77, 98.7 %). The most common OCR ICD-O-M
code found among these patients was 9750/3 (68, 88.3 % -
malignant histiocytosis). Using OCR ICD-9 codes would
have correctly identified 68 (88.3 %) of these patients.
Discussion
To our knowledge, this is the first study to systematically
examine the validity of diagnosis data for cases of child-
hood cancer in a general cancer registry. In doing so, we
have shown that while excellent agreement was achieved
within most broad diagnostic categories and for some spe-
cific diagnoses, agreement among several common child-
hood malignancies was poor to dismal.
The predominant source of error was the derivation of
incorrect ICD-O-M codes from source documents, and
the consequent assignment of inappropriate ICCC-3
diagnostic groups and/or subgroups. This was in most
cases due to the inappropriate assignment of patients
with specific diagnoses to “other” or “miscellaneous” cat-
egories, as reflected by the higher number of patients in
such categories based on OCR data as compared to
POGONIS data, as opposed to misclassification among
different specific types of childhood cancer. This was ap-
parent both within specific diagnostic groups (e.g. 73
POGONIS-assigned patients to the “other central ner-
vous system - CNS - tumors” subgroup as compared to
144 OCR-assigned patients) and overall (23 versus 259
patients in Diagnostic Group XII – other and unspeci-
fied malignant neoplasms).
The magnitude of this problem varied between diagnos-
tic subgroups. The OCR was able to consistently identify
unique childhood solid tumors (e.g. neuroblastoma, ret-
inoblastoma, Wilms tumor, hepatoblastoma) as demon-
strated by near perfect, and in some cases perfect,
measures of agreement. Hematologic and CNS cancers
were however more problematic. For example, a diagnosis
of ALL, the most common childhood cancer, in OCR car-
ried a sensitivity of only 0.71. Almost no patient with Bur-
kitts lymphoma was correctly identified by the OCR.
Previous studies in adults have identified similar issues
among non-Hodgkin lymphomas (NHL). Clarke et al. ex-
amined the validity of NHL diagnoses among adults in the
Greater Bay Area Cancer Registry, and found that agree-
ment on subtype classification was only 59 %, with the
positive predictive values of specific subtypes reaching as
low as 0.05 [20]. In later work, the same group found that
almost half of the adult lymphomas recorded as unclassifi-
able in their registry could in fact be assigned a specific
subtype [21].
Our findings have important implications for individuals
using cancer registry data. Population-based incidence de-
rived from cancer registries for hematologic and CNS
pediatric malignancies may represent significant underes-
timates, as a proportion of children with these cancers are
misclassified into “miscellaneous” categories. More gener-
ally, this study demonstrates the pitfalls in designating
passive cancer registry data as a gold standard in less com-
mon malignancies such as childhood cancer. Our results
also illustrate the importance of conducting registry valid-
ation studies, particularly given their growing importance
in guiding cancer policy [1].
Our results also indicate that pediatric cancer specific
algorithms, training and personnel may be necessary to
improve the accuracy of data pertaining to several com-
mon childhood malignancies. This may be particularly
relevant to more complex and rare childhood cases. It is
noteworthy that in several cases, the ICD-O-M was in-
correctly assigned in OCR despite OCR ICD-9 codes
that agreed with the POGONIS diagnosis. For example,
nearly all patients diagnosed with Burkitts lymphoma ac-
cording to POGONIS received ICD-O-M codes in OCR
indicating “malignant histiocytosis”, despite OCR ICD-9
codes that in the majority of cases also indicated Bur-
kitts lymphoma. This suggests that the accuracy of can-
cer registry morphology data, particularly in hematologic
malignancies, may be improved, but not perfected by
comparing it to ICD-9 data. Similarly, researchers wish-
ing to identify cohorts of childhood cancer patients from
registry data should consider validating algorithms based
on ICD-O-3 codes, as suggested by the ICCC-3, against
more complex algorithms that also incorporate ICD-9
codes prior to analyzing these cohorts. Finally, our find-
ings also suggest that registries may benefit from auto-
matically reviewing all pediatric cases assigned to
“miscellaneous” or “unclassifiable” categories. Given the
small number of pediatric cases relative to the overall
cancer burden, implementing these strategies may not
require significant additional resources. Their validity
however remains theoretical and warrants further study.
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Indeed, the involvement of national and international
bodies such as the International Agency for Cancer Re-
search (IARC) and the International Association of Can-
cer Registries may aid in designing, implementing and
evaluating these strategies.
One limitation of this study pertains to the
generalizability of its results to other cancer registries. As
noted above, during the study period the OCR relied upon
passive algorithms to reconcile information on histology
from several sources. Other cancer registries utilize other
strategies; for example, the use of hospital-based computer-
ized reporting systems that enable centers to transmit
registry-reportable information [20]. Whether the validity
of diagnostic data collected by registries using these alterna-
tive strategies differs from that in the current study is un-
known, though the study cited above demonstrating the
poor validity of NHL diagnoses in adults was conducted
using such a cancer registry. Interestingly however, in a re-
port from the Surveillance, Epidemiology, and End Results
(SEER) group of cancer registries on childhood cancer be-
tween 1975–1995, only 0.3–0.8 % of cases were classified in
Diagnostic Group XII (Other and unspecified malignant
neoplasms), [22] in line with the 0.5 % in POGONIS in the
current study but below the 6.3 % of cases in the OCR. The
OCR is in fact currently developing new algorithms and
allowing for manual edits where applicable; future work will
examine the impact of these changes on data validity.
Strengths of this study include its population-based na-
ture and large sample size, allowing conclusions to be
drawn for specific diagnostic subgroups. This was feasible
due to the presence of an independent active childhood
cancer registry. In many jurisdictions where no such child-
hood cancer registry exists, validation would require more
onerous chart abstraction. Several additional limitations
however also merit notice. First, we were unable to link
9.4 % of cohort patients to OCR data. We cannot rule out
systematic differences between these patients and the rest
of the cohort that may have impacted our results. Second,
our study did not have access to ICD-O-T codes, though
ICD-9 codes indicating site were used as a substitute.
Third, the premise of the POGONIS diagnosis as gold
standard is an assumption; this assumption is however rea-
sonable given active and near real-time data entry with clin-
ician oversight. It should also be noted however that while
POGONIS may be considered complete and population-
based for children aged <15 years at diagnosis, it is not for
those aged 15 or older. OCR by contrast is of course
population-based for all ages. Indeed the completeness of
OCR has been demonstrated in a prior comparison with
POGONIS data [11].
Conclusions
In conclusion, we have shown that while the validity of
OCR data was generally excellent across most broad
diagnostic groups and some specific subgroups, misclassifi-
cation of hematologic and CNS tumors among children
was common. These findings have important implications
for those using cancer registry data to conduct pediatric
cancer research or guide policy. Though more active
methods of cancer registration may theoretically result in
greater validity, validation studies of pediatric data in other
cancer registries should be conducted to identify practices
and procedures leading to the highest quality information.
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